Respiratory Tract Neoplasms: Clinical Trials

4835 completed, 1974 unknown, 1937 recruiting, 1366 terminated. 4482 Phase 2, 2768 Phase 1, 2042 Not applicable, 1145 Phase 3, 166 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	4482	Completed 1709, Unknown 712, Recruiting 669, Terminated 610, Active not recruiting 327, Not yet recruiting 241, Withdrawn 192, Suspended 14, Enrolling by invitation 8
Phase 1	2768	Completed 1109, Terminated 500, Recruiting 477, Active not recruiting 242, Unknown 239, Withdrawn 101, Not yet recruiting 78, Suspended 17, Enrolling by invitation 5
Not applicable	2042	Completed 803, Recruiting 371, Unknown 364, Terminated 152, Not yet recruiting 151, Active not recruiting 116, Withdrawn 69, Enrolling by invitation 13, Suspended 3
Phase 3	1145	Completed 455, Recruiting 172, Unknown 164, Terminated 140, Active not recruiting 135, Not yet recruiting 51, Withdrawn 23, Enrolling by invitation 3, Suspended 2
Phase 4	166	Completed 75, Unknown 32, Recruiting 20, Terminated 18, Not yet recruiting 10, Active not recruiting 4, Withdrawn 4, Suspended 3
Early Phase 1	120	Completed 30, Unknown 25, Terminated 19, Recruiting 17, Not yet recruiting 12, Withdrawn 8, Active not recruiting 4, Enrolling by invitation 3, Suspended 2

Follow Respiratory Tract Neoplasms: new trials by email Literature Review of Respiratory Tract Neoplasms trials Research Report on Respiratory Tract Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer Individualized pre-operative physical exercise, Post-operative rehabilitation physical exercise, Respiratory physiotherapy Prehabilitation - Lung Cancer	Not applicable	Not yet recruiting	FranciscoVeraSerrano	84	2028-01-01	2026-03-17
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	RemeGen Co., Ltd.	26	2027-12-01	2026-09-22
Symptom Management to Improve Completion of Patient-reported Outcome Measures Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management - Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm	Not applicable	Not yet recruiting	Henry Ford Health System	78	2027-10-01	2026-07-29
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods Real-Time Image Guided Radio Therapy (IGRT) - Cancer	Not applicable	Not yet recruiting	University of Sydney	40	2027-06-01	2026-05-20
Antigen-specific T Cells Against Lung Cancer Lung cancer-specific T cells - Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	20	2027-06-01	2026-11-02
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab PANDA-VAC, Pembrolizumab - Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer	Phase 1	Suspended	UNC Lineberger Comprehensive Cancer Center	6	2027-05-20	2026-04-23
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records Lung Cancer		Not yet recruiting	AstraZeneca	3000	2027-04-01	2026-06-02
A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC) Zanidatamab, Zongertinib - Non Small Cell Lung Cancer	Phase 1	Not yet recruiting	M.D. Anderson Cancer Center	24	2027-04-01	2026-10-28
Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable, Non-Targetable Stage III Non Small Cell Lung Cancer (NSCLC) Moderately Hypofractionated Radiotherapy, Conventionally Fractionated Radiotherapy - Stage III NSCLC	Not applicable	Not yet recruiting	Trans Tasman Radiation Oncology Group	300	2027-03-30	2026-11-06
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection - Lung Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	336	2027-03-02	2026-11-05
Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung	Phase 1 / Phase 2	Not yet recruiting	Xemed LLC	10	2027-03-01	2026-09-01
Virtual Reality in Lung Cancer Patients Immersive Virtual Reality - Lung Neoplasms (D008175)	Not applicable	Not yet recruiting	Dott.Claudio Sini	60	2027-03-01	2026-08-12
Using an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors Artificial Intelligence-based Intervention, Best Practice, Computed Tomography - Lung Carcinoma, Lung Non-Small Cell Carcinoma	Not applicable	Not yet recruiting	Northwestern University	34	2027-02-13	2026-10-27
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 1	Recruiting	National Cancer Institute (NCI)	39	2027-02-13	2026-10-29
DK222 Study at Hopkins [18F]DK222 radiotracer - Non-Small Cell Lung Cancer, Urothelial Cancer	Phase 1	Recruiting	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	6	2027-01-31	2026-09-29
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin - Extensive-stage Small-cell Lung Cancer	Phase 1	Suspended	University of Maryland, Baltimore	50	2027-01-30	2026-09-14
Witness Project Lung Witness Project Lung, General Educational Program - Lung Cancer	Not applicable	Not yet recruiting	Hackensack Meridian Health	400	2027-01-15	2026-08-28
Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1 / Phase 2	Not yet recruiting	Nob Hill Therapeutics, Inc.	100	2027-01-11	2026-10-08
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer	Phase 3	Not yet recruiting	AbbVie	660	2027-01-06	2026-10-05
Effects of Supervised Aerobic Exercise on Biomarkers in Patients With nSCLC Receiving Immunotherapy Exercise - Non-Small Cell Lung Cancer, Aerobic Exercise	Not applicable	Not yet recruiting	Izmir Bakircay University	78	2027-01-04	2026-10-21

Showing 20 of 12153. Sign in to see all of them.

Narrower conditions

Carcinoma, Non-Small-Cell Lung (7095)  ·  Lung Neoplasms (5273)  ·  Small Cell Lung Carcinoma (1206)  ·  Breast Neoplasms (886)  ·  Neoplasms (776)  ·  Colorectal Neoplasms (697)  ·  Melanoma (571)  ·  Ovarian Neoplasms (509)  ·  Neoplasm Metastasis (493)  ·  Pancreatic Neoplasms (492)  ·  Head and Neck Neoplasms (461)  ·  Stomach Neoplasms (412)  ·  Adenocarcinoma of Lung (404)  ·  Squamous Cell Carcinoma of Head and Neck (386)  ·  Prostatic Neoplasms (378)

Broader conditions

Neoplasms by Site (12100)  ·  Respiratory Tract Diseases (11968)  ·  Thoracic Neoplasms (11830)  ·  Lung Diseases (11521)  ·  Neoplasms (11377)  ·  Bronchial Neoplasms (7935)  ·  Carcinoma, Bronchogenic (7916)  ·  Lung Neoplasms (6517)  ·  Neoplasms by Histologic Type (2427)  ·  Neoplasms, Glandular and Epithelial (2041)  ·  Digestive System Diseases (1532)  ·  Digestive System Neoplasms (1490)  ·  Carcinoma (1440)  ·  Skin and Connective Tissue Diseases (1424)

Interventions

Carboplatin (1094)  ·  Cisplatin (853)  ·  Pemetrexed (761)  ·  pembrolizumab (596)  ·  Paclitaxel (583)  ·  Docetaxel (512)  ·  Gemcitabine (398)  ·  Radiotherapy (394)  ·  Erlotinib Hydrochloride (339)  ·  Nivolumab (323)  ·  Bevacizumab (295)  ·  Etoposide (265)  ·  durvalumab (240)  ·  Drug Therapy (231)  ·  osimertinib (211)

Sponsors

National Cancer Institute (NCI) (327)  ·  AstraZeneca (235)  ·  M.D. Anderson Cancer Center (204)  ·  Memorial Sloan Kettering Cancer Center (167)  ·  Eli Lilly and Company (160)  ·  Pfizer (140)  ·  Sun Yat-sen University (126)  ·  Bristol-Myers Squibb (112)  ·  Novartis Pharmaceuticals (110)  ·  Hoffmann-La Roche (105)  ·  Alliance for Clinical Trials in Oncology (97)  ·  Merck Sharp & Dohme LLC (95)  ·  Shanghai Chest Hospital (92)  ·  Shanghai Pulmonary Hospital, Shanghai, China (87)  ·  Fudan University (82)

Countries

United States (5142)  ·  China (2702)  ·  France (1175)  ·  Spain (1010)  ·  Italy (940)  ·  Canada (933)  ·  South Korea (864)  ·  United Kingdom (798)  ·  Germany (766)  ·  Taiwan (627)  ·  Australia (600)  ·  Netherlands (570)  ·  Belgium (538)  ·  Japan (517)  ·  Poland (478)

Top investigators

Mariano Provencio, MD (21)

Results publications

PMID 27130468, PMID 33538338, PMID 37419867, PMID 40311309, PMID 21714641, PMID 22586319, PMID 23442309, PMID 26291008, PMID 26291023, PMID 27718847, PMID 30207593, PMID 34870327, PMID 37465924, PMID 39113428, PMID 39462179, PMID 42820295, PMID 19692680, PMID 25175099, PMID 25881079, PMID 26104945, PMID 27959700, PMID 29658848, PMID 30280641, PMID 33337539, PMID 35537408, PMID 36184621, PMID 37934000, PMID 38642841, PMID 16757720, PMID 16966690, PMID 19801201, PMID 23816960, PMID 24705333, PMID 25436806, PMID 25490004, PMID 25589191, PMID 26028407, PMID 26051236, PMID 26768165, PMID 26823294, PMID 27458945, PMID 28445469, PMID 28472437, PMID 28501139, PMID 28885881, PMID 29151359, PMID 29290251, PMID 29293889, PMID 29653820, PMID 29658856

NIH funding

2023 (149), 2016 (69), 2017 (68), 2025 (63), 2018 (61), 2019 (61), 2015 (55), 2014 (52), U10CA031946 (52), U10CA032102 (39), P30CA033572 (32), U10CA180888 (30), P30CA012197 (28), 2009 (25), 2008 (23)